Novotech and CTTQ Pharma Secure World’s First Approval of Anlotinib-Chemotherapy Combo for Advanced Soft Tissue Sarcoma

-Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Grou...

August 29, 2025 | Friday | News
TREOS Bio Secures $2.1M Bridge Financing to Advance Phase II Trial in Colorectal Cancer

Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, a...

August 28, 2025 | Thursday | News
BriaCell Secures $2.05 Million NCI Grant to Advance Bria-PROS+™ Immunotherapy in Metastatic Prostate Cancer

  US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase...

August 26, 2025 | Tuesday | News
BlossomHill Therapeutics Doses First Patient in SOLARA Trial Expansion of First-in-Class OMNI-EGFR™ Inhibitor

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines ...

August 25, 2025 | Monday | News
Novocure Submits PMA to FDA for Tumor Treating Fields Therapy in Pancreatic Cancer

Novocure announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields...

August 21, 2025 | Thursday | News
Tivic Health Acquires Entolimod™ INDs to Advance ARS and Cancer Trials

INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia ...

August 21, 2025 | Thursday | News
MAIA Biotechnology Secures European Patent for Next-Generation Telomere-Targeting Cancer Therapies

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on dev...

August 14, 2025 | Thursday | News
Bayer and Kumquat Biosciences Partner to Develop First-in-Class KRAS G12D Inhibitor for Hard-to-Treat Cancers

Collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancr...

August 13, 2025 | Wednesday | News
Massive Bio and Prognos Health Forge Exclusive Partnership to Advance AI-Enabled Oncology Trial Matching

-Massive Bio, a leader in AI-enabled oncology trial matching and patient access, and Prognos Health, a provider of actionable lab data,  announced a...

August 13, 2025 | Wednesday | News
Fosun Pharma Grants Global Rights (Ex-China) for Innovative Respiratory Drug XH-S004 to Expedition Therapeutics

Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics ...

August 12, 2025 | Tuesday | News
Akeso Doses First Patient in Phase III Trial of Ivonescimab for Limited-Stage Small Cell Lung Cancer

Akeso, Inc.announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating...

August 11, 2025 | Monday | News
Junshi Biosciences’ sNDA for Toripalimab Plus Disitamab Vedotin in HER2-Expressing Urothelial Carcinoma Accepted by China’s NMPA

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...

August 11, 2025 | Monday | News
Exact Sciences Secures Exclusive U.S. Rights to Freenome’s Blood-Based Colorectal Cancer Screening Tests

Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome sub...

August 07, 2025 | Thursday | News
Janux Therapeutics Achieves $10 Million Milestone as First Patient Dosed in Merck Collaboration Trial

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (Nasdaq: JANX...

August 06, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close